Every practice coaches childhood immunizations. The Childhood Immunization Status measure gets a per-dose tracker, a well-visit cadence, and a parent script that staff can recite by their second week [1]. Almost nobody coaches the adolescent version with the same rigor. Yet adolescent immunizations — the HEDIS Immunizations for Adolescents (IMA) measure — close only when three separate antigens are all complete by the 13th birthday, and the window to capture them is narrow, seasonal, and easy to miss. The result is a measure that quietly stays open while everyone’s attention sits one age band lower.
Why IMA Goes Under-Coached
The childhood measure has a structural advantage: it lives inside a dense schedule of well-baby visits, so the doses get prompted at nearly every encounter through the second birthday [1]. IMA does not have that scaffolding. The 11-to-12-year-old patient often has only one well visit in the entire window, and the antigens involved — meningococcal (MCV4), Tdap, and the HPV series — feel optional to families in a way that infant shots do not [2].
There is also a counting problem. IMA Combo 2 requires meningococcal conjugate (MCV4), the tetanus-diphtheria-acellular-pertussis booster (Tdap), and a complete HPV series — three immunizations — all done before the 13th birthday [3]. Miss any one and the measure stays open for that adolescent, full stop. A practice can administer two of the three, feel productive, and still close nothing.
What Actually Closes the Measure
The three antigens and their windows
IMA Combo 2 closes on three components by the adolescent’s 13th birthday [3]. MCV4 (meningococcal) and Tdap are each a single dose, given in the early-adolescent window [3]. The HPV series is the third component — and the one that trips most practices up, because it is a series, not a single shot.
The HPV start-at-9 early lever
Here is the lever almost nobody pulls: HPV vaccination can begin at age 9 [4]. When the first dose is given between ages 9 and 14, the schedule is only two doses, with the second dose 6 to 12 months after the first [2]. Wait until 15 or older, or for an immunocompromised patient, and it becomes a three-dose series — dose two at 1 to 2 months, dose three at 6 months after the first [2]. Starting at 9 turns a three-shot problem into a two-shot problem and buys a full year of runway before the 13th-birthday deadline. It is the single most powerful move on this measure.
“Up to date” notations do not count
The same documentation discipline that governs the childhood measure applies here: a chart note reading “child is up to date with all immunizations” does not meet compliance criteria [1]. The measure needs discrete, dated immunization records — each dose documented with its administration date, ideally captured in your state immunization registry [1]. A vague attestation closes nothing.
Coaching the Measure in Practice
Open adolescent doses are invisible until the patient is already in the room — or already gone. Chart Prep solves this by surfacing open preventions and screenings before the visit, as a pre-visit chart summary you can bulk-print for the day’s schedule [5]. Run it ahead of the back-to-school rush and the open MCV4, Tdap, and HPV doses are on the page before the adolescent sits down.
Staff cannot always tell how close an adolescent is to closing IMA. CareEmpower®’s IMA Combo 2 view carries a per-dose counter — three immunizations required to move the gap to Marked for Closure, with each antigen toggled individually [3]. It mirrors the per-dose mechanic your team already knows from the childhood measure, so the muscle memory transfers. Staff see at a glance whether a patient needs all three or just the second HPV dose.
The work gets done but does not get paid. In the markets where IMA is an Equality Care Incentive Program (ECIP) Prevention & Screenings activity, closure is payable once the health plan confirms it through claims data — no chart upload required for that pillar [6]. The dose has to be administered, coded, and confirmed; “up to date” language will not trigger it. Your Practice Performance Advisor (PPA) coaches this loop, the same way they coach the rest of the ECIP workflow [6].
The capture moment is back-to-school. Tdap and MCV4 are common school-entry requirements in many states, which means the 11-to-12-year-old already has a reason to be in your office in July and August. That visit is the natural window to capture all three antigens at once — and to start HPV if it has not begun [2][4].
The Long Game
Closing IMA is a quality win this year. Starting HPV at 9 is something larger. The adolescent you vaccinate today is the adult who never shows up in your cervical, oropharyngeal, or anal cancer numbers a generation from now [4]. Adolescent immunizations are the rare measure where the box you check and the life you change are the same act. Coach IMA like it matters this much, because it does — and the back-to-school visit is where it starts.
